ArticleDiscover oncology2026
Integrated proteomic and single-nucleus transcriptomic profiling identifies prognostic markers and therapeutic targets in glioblastoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Glioblastoma (GBM) is the most aggressive primary malignant brain tumor in adults and remains associated with marked heterogeneity and poor prognosis. To identify prognostic biomarkers and characterize their cellular contexts, we integrated public proteomic and single-nucleus transcriptomic datasets. Protein expression data from the TCPA GBM cohort were used to construct a prognostic model by univariate and multivariable Cox regression analyses, followed by Kaplan-Meier survival, time-dependent ROC, and nomogram analyses. Single-nucleus RNA-seq data from GSE138794 were used to define the cellular distribution of model proteins and to perform marker-centered functional analyses. A four-protein signature consisting of BCL2, CTNNB1, CHEK2, and NDRG1_pT346 was established. The derived risk score significantly stratified patients into high- and low-risk groups with distinct overall survival and progression-free survival outcomes, and remained independently associated with prognosis after adjustment for clinical covariates. In the single-cell atlas, inferCNV-guided refinement identified malignant glioma cells and further resolved them into Glioma_MES, Glioma_PN, and Glioma_CL states. The four prognostic markers showed distinct cellular preferences: BCL2 and NDRG1 were mainly enriched in oligodendroglial-related populations and selected glioma states, whereas CHEK2 and CTNNB1 were more highly expressed in myeloid-associated populations. Among the four markers, only CHEK2- and NDRG1-defined malignant glioma subgroups showed sufficient transcriptional divergence for downstream analysis. CHEK2-positive glioma cells were enriched for DNA replication, chromosome segregation, DNA damage response, and checkpoint-related programs, whereas NDRG1-positive glioma cells were characterized by hypoxia response, glycolysis, and metabolic adaptation. CellChat analysis further revealed distinct communication patterns for CHEK2- and NDRG1-associated malignant glioma cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.